Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02735707 · ClinicalTrials.gov registry record · Phase 3
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
A Phase 3 study of Community-acquired Pneumonia, Influenza, COVID-19, sponsored by UMC Utrecht.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 20,000
- Enrollment target
- 20
- Study locations
NCT02735707: Recruiting Phase 3 study of Community-acquired Pneumonia, Influenza, COVID-19, sponsored by UMC Utrecht.
NCT02735707 is a Phase 3 study of Community-acquired Pneumonia, Influenza, COVID-19 that is actively recruiting participants, run by UMC Utrecht. The registered enrollment target is 20,000 participants, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (2494% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02735707, a Phase 3 study of Community-acquired Pneumonia, Influenza, COVID-19, is actively recruiting participants, sponsored by UMC Utrecht.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 20,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia. In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic such as COVID-19. REMAP-COVID is a sub-platform of REMAP-CAP that evaluates treatments specific to COVID-19 in the United States of America.
Conditions Studied
Interventions
- DRUG Amoxicillin-clavulanate
- DRUG Ceftriaxone
- DRUG Moxifloxacin or Levofloxacin
- DRUG Piperacillin-tazobactam
- DRUG Ceftaroline
Study Locations (20)
New South Wales
- Bankstown-Lidcombe Hospital - Bankstown
- Blacktown Hospital - Blacktown
- Campbelltown Hospital - Campbelltown
- Sutherland Hospital - Caringbah
- Concord Hospital - Concord
- Dubbo Base Hospital - Dubbo
- Northern Beaches Hospital - Frenchs Forest
- Nepean Hospital - Kingswood
Florida
- University of Florida - Jacksonville
Georgia
- Augusta University - Augusta
Illinois
- University of Illinois Health - Chicago
Louisiana
- Tulane Medical Center - New Orleans
Michigan
- University of Michigan - Ann Arbor
New York
- Memorial Sloan Kettering Cancer Center - New York
North Carolina
- Wake Forest Baptist Health - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20,000 participants |
| Start Date | 2016-04-11 |
| Est. Completion | 2028-02 |
| Phase | Phase 3 |
What NCT02735707 shows while recruiting
NCT02735707 is an interventional study that assigns participants to a tested intervention. Its 20,000 participants enrollment target places it among the larger protocols in the corpus, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (2494% higher).
The record links to 1 condition, with Community-acquired Pneumonia, Influenza, COVID-19 appearing as the primary indexed condition, and to 5 interventions - of which Amoxicillin-clavulanate is the first listed.
NCT02735707 names 20 study sites across 13 states, led by New South Wales, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT02735707 about?
NCT02735707 is a clinical study titled "Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia". REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia. In addition, R...
What is the current status of trial NCT02735707?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 20,000 participants. The study started on 2016-04-11. Estimated completion is 2028-02.
What conditions does trial NCT02735707 study?
This clinical trial studies the following conditions: Community-acquired Pneumonia, Influenza, COVID-19.
What interventions are being tested in trial NCT02735707?
The interventions under investigation include: Amoxicillin-clavulanate (DRUG), Ceftriaxone (DRUG), Moxifloxacin or Levofloxacin (DRUG), Piperacillin-tazobactam (DRUG), Ceftaroline (DRUG).
Who is sponsoring clinical trial NCT02735707?
This trial is sponsored by UMC Utrecht, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02735707 being conducted?
This trial has 20 study locations across Florida, Georgia, Illinois, Louisiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02735707's enrollment target sits among peer trials
20,000 10th of 2000 higher than 1,991 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00271180 · 20,000 participants
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
- NCT00830557 · 20,000 participants
Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders
- NCT00900471 · 20,000 participants
Collection and Storage of Tissue Samples From Patients Undergoing Surgery For Suspected Solid Tumors
- NCT03115710 · 20,000 participants
The K-Map Study, Global Prevalence of KC
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI